Cirrhosis News and Research

Latest Cirrhosis News and Research

Novel scrapbook-inspired test helps patients diagnosed with hepatitis C

To the relief of patients diagnosed with hepatitis C, the U.S. Food and Drug Administration approved two new treatments late last year, and a few more are on the way.

22 May 2014

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

RNA interference (RNAi) is a naturally occurring process, which cells can use to silence, or ‘turn off’ unwanted genes.

From Quest Diagnostics 19 May 2014

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Janssen-Cilag International NV today announced that its next generation protease inhibitor (PI) OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C (CHC), in combination with other medicinal products.

16 May 2014

Scientists decrypt interaction network of hepatitis C virus proteins in living human cells

Scientists at the Helmholtz Zentrum München have for the first time decrypted the interaction network of hepatitis C virus proteins in living human cells. Their findings will contribute to a better understanding of the mechanisms behind inflammatory liver disease caused by hepatitis C viruses and open up new avenues for therapy development.

9 May 2014

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2014, and other business updates.

9 May 2014

Hepatocellular carcinoma on the rise among Mexican Americans

Hepatocellular carcinoma (HCC), the primary cancer of the liver, is on the verge of becoming an epidemic among Mexican Americans, especially in Texas.

8 May 2014

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.

8 May 2014

Snacking linked with abdominal fat and fatty liver

Researchers from The Netherlands found that snacking on high-fat and high-sugar foods was independently associated with abdominal fat and fatty liver (hepatic steatosis).

7 May 2014

Liver cancer screening in cirrhosis patients improves survival rates

Liver cancer survival rates could be improved if more people with cirrhosis are screened for tumors using inexpensive ultrasound scans and blood tests, according to a review by doctors at UT Southwestern Medical Center.

6 May 2014

High-dose steroid therapy following surgery do not improve bile drainage among infants

Among infants who underwent surgery to repair bile ducts that do not drain properly (biliary atresia), the administration of high-dose steroid therapy following surgery did not significantly improve bile drainage after 6 months, although a small clinical benefit could not be excluded, according to a study in the May 7 issue of JAMA, a theme issue on child health.

5 May 2014

Study: New combination therapy to treat chronic hepatitis C

A new combination therapy allows chronic hepatitis C to be treated in a manner that is less aggressive yet equally efficient.

5 May 2014

Study shows reversal of early-stage liver fibrosis after bariatric surgery

Bariatric surgery, which is best known for its ability to help patients lose substantial weight, can also result in significant improvement in nonalcoholic fatty liver disease (NAFLD), according to new research presented today at Digestive Disease Week- (DDW).

5 May 2014

Can-Fite BioPharma submits study protocol to FDA for CF102 Phase II trial for advanced liver cancer

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has submitted a study protocol to the U.S. Food and Drug Administration for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.

29 Apr 2014

Discovery offers potential target for reversing progression of end-stage liver disease

A team of researchers in the University of Arizona's College of Pharmacy has discovered a molecular pathway that could be key to creating new therapeutics that would slow or even reverse the progression of end-stage liver disease.

26 Apr 2014

Study helps physicians better identify patients at risk of acute respiratory distress syndrome

Acute respiratory distress syndrome is a leading cause of respiratory failure after surgery. Patients who develop the lung disorder postoperatively are at higher risk of dying in the hospital, and those who survive the syndrome may still bear its physical effects years later.

22 Apr 2014

Synageva announces publication of LAL Deficiency review in Atherosclerosis

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced the publication of an overview of lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Atherosclerosis, the official journal of the European Atherosclerosis Society.

21 Apr 2014

Cirrhosis News and Research

Latest Cirrhosis News and Research

Novel scrapbook-inspired test helps patients diagnosed with hepatitis C

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Scientists decrypt interaction network of hepatitis C virus proteins in living human cells

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Hepatocellular carcinoma on the rise among Mexican Americans

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Snacking linked with abdominal fat and fatty liver

Liver cancer screening in cirrhosis patients improves survival rates

High-dose steroid therapy following surgery do not improve bile drainage among infants

Study: New combination therapy to treat chronic hepatitis C

Study shows reversal of early-stage liver fibrosis after bariatric surgery

Can-Fite BioPharma submits study protocol to FDA for CF102 Phase II trial for advanced liver cancer

Discovery offers potential target for reversing progression of end-stage liver disease

Study helps physicians better identify patients at risk of acute respiratory distress syndrome

Synageva announces publication of LAL Deficiency review in Atherosclerosis

Northwestern Medicine study provides new insights on tissue scarring in scleroderma

Deaths from viral Hepatitis B and C exceed deaths caused by HIV/AIDS

New data focuses on different approaches to improve diagnosis and treatment of HCC

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Cirrhosis News and Research

Latest Cirrhosis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in